Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients.

We retrospectively collected clinical data on 31 relapsed or refractory acute myeloid leukemia (R/R AML) patients who were treated with outpatient glasdegib and low-dose Cytarabine (LDAraC) at our institution. The median age was 67 years (45-86). The median Eastern Cooperative Oncology Group performance status was 2 (1-3). The patients had previously received a median number of 2 (1-4) treatment lines, 61% (19/31) had been treated with intensive chemotherapy, 29% (9/31) had relapsed after allogeneic stem cell transplantation, and 45% (14/31) had had venetoclax exposure. Adverse cytogenetics were identified in 45% (14/31) of the cases. The CR + CRp rate was 21% (6/29) among evaluable patients. The median overall survival was 3.9 months for all patients. Different median overall survival times were observed in responders, patients achieving stable disease and those diagnosed with progressive disease: not reached vs 3.9 months vs 0.8 months, respectively (p < 0.001). The most common adverse events were pneumonia (29%, 9/31), sepsis (23%, 7/31), and febrile neutropenia (16%, 5/31). Glasdegib + LDAraC is a fairly safe, non-intensive, outpatient regimen inducing complete remission and resulting in prolonged survival in some R/R AML patients.

Introduction

The prognosis of relapsed or refractory acute myeloid leukemia (R/R AML) in elderly and unfit population remains poor as intensive salvage chemotherapy regimens cannot be administered due to excessive toxicity whereas standard low-intensity therapies often lack efficacy [1, 2]. During the last decade, a number of targeted therapies have shown promising efficacy in frontline and R/R AML settings including elderly and frail patients [3, 4]. Glasdegib is a novel small-molecule inhibitor of the Smoothened (SMO) receptor, and its efficacy is based on downregulation of the Hedgehog signaling pathway which is involved in the resistance of AML cells [5-7]. Glasdegib combined with low dose Cytarabine (LDAraC) is currently approved for newly diagnosed AML patients unfit for standard chemotherapy [8]. The pivotal phase II BRIGHT AML 1003 trial demonstrated a higher complete remission rate (17% vs 2.3%) and significantly longer median overall survival (8.8 vs 4.9 months) in unfit newly diagnosed AML patients receiving Glasdegib + LDAraC compared to the comparator arm treated with LDAraC only [9]. Cortes et al. had also presented positive efficacy, safety, and survival outcomes of AML/high-risk myelodysplastic syndrome (HR-MDS) patients treated with glasdegib in combination with standard induction 7 + 3 [10]. Glasdegib is currently being evaluated in a phase III trial in combination with either azacitidine or standard induction 7 + 3 (BRIGHT AML 1019) for previously untreated AML and several other phase I–II studies [11]. Nevertheless, glasdegib data in the R/R AML setting are lacking. We present the results of 31 heavily pretreated, elderly, and unfit R/R AML patients who were treated with glasdegib + LDAraC.

Methods

We retrospectively collected clinical data on R/R AML patients who were treated with glasdegib + LDAraC in 2018–2020 at Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. Glasdegib was provided via a Compassionate Use Program by Pfizer, and the treatment was approved by the local Ethics Committee on a case by case basis. The data collection was approved by Vilnius Regional Biomedical Research Ethics Committee. All patients were at least 18 years of age, had R/R AML with no active infection or life-threatening organ toxicity, and had all treatment options exhausted.

Glasdegib + LDAraC

The treatment cycles consisted of self-administered Cytarabine 20 mg/m2 s/c days 1–10 and glasdegib 100 mg p/o daily on an outpatient basis. The cycles were repeated every 28–35 days; longer interruptions were allowed in case of toxicity or social reasons. Glasdegib was continued after day 28 even if the start of the next cycle was postponed. Indications for stopping the treatment were progressive disease with no further clinical benefit observed by the treating physician, and excessive toxicity or availability of alternative treatment strategies. Routine ECG evaluation every 1–4 weeks and potassium ± magnesium supplements were administered to reduce the risk of QT prolongation in the majority of cases. Strong CYP3A4 inhibitors or drugs prolonging the QT interval were allowed if alternatives were not available; however, ECG evaluation was repeated more frequently in such cases.

Endpoints and statistical analysis

Descriptive statistics were used for baseline characteristics, safety, and efficacy analysis. For efficacy analysis, we calculated the overall response rate (ORR), which consisted of complete remission (CR), complete remission with incomplete hematological recovery (CRi), and complete remission with incomplete platelet recovery (CRp) or partial remission (PR) as defined by the European Leukemia Network 2017 (ELN 2017) criteria [12]. We calculated day 30 and day 60 mortality and recorded grade 3–5 non-hematological adverse events according to the Common Terminology Criteria of Adverse Events (CTCAE v5.0) scale. For additional toxicity evaluation, we also analyzed the prevalence of dysgeusia, anorexia, alopecia, QT prolongation, and gastrointestinal symptoms as adverse events of special interest related to glasdegib.

Fisher’s exact and Mann–Whitney U tests were used for comparison of ordinal and numerical data between the groups. Kaplan–Meier analysis was used for overall survival (OS). OS was estimated from treatment start to death from any cause with live patients censored on their last follow-up date. Reverse Kaplan–Meier analysis was used for median follow-up time evaluation. The log-rank test was used for the intergroup comparison of survival data. Univariate Cox regression analysis was used to evaluate the effect of different variables on OS. Data cutoff date was November 16, 2020. Difference with p < 0.05 was considered statistically significant.

Results

Thirty-one patients (17 female) were included in the study. Detailed baseline characteristics are summarized in Table 1. The median age was 67 years (45–86); 48% (15/31) of the patients were older than 70 years. The median Eastern Cooperative Oncology Group performance status (ECOG PS) was 2 (1–3). The patients had previously received a median number of 2 treatment lines; 29% (9/31) had been treated with 3 or 4 lines of therapy. Sixty-one percent (19/31) had previously received intensive chemotherapy regimens and 13% (4/31) had primary refractory AML. Twenty-nine percent (9/31) had relapsed after allogeneic stem cell transplantation (alloSCT). The median time from alloSCT to relapse was 89 days (51–3177) and all but one had relapsed within 12 months of alloSCT. Thirty-nine percent (12/31) had received only low-intensity therapies (hypomethylating agents (HMA)/LDAraC ± venetoclax). Of note, 45% (14/31) had previous venetoclax exposure in combination with various regimens. Adverse cytogenetics were identified in 45% (14/31) of patients, of whom 5 (16%) had complex karyotype. The most common mutations were IDH1/2 (23%, 7/31), NPM1 (16%, 5/31), ASXL1 (13%, 4/31), RUNX1 (13%, 4/31), NRAS/KRAS (10%, 3/31), FLT3-ITD/TKD (10%, 3/31), and TP53 (10%, 3/31). Based on the ELN2017 risk group stratification criteria, 16% (5/31), 26% (8/31), and 58% (18/31) of the patients were stratified into favorable, intermediate, and adverse risk groups, respectively.

Table 1

Baseline characteristics

	n/N (%)
Gender
Male	14/31 (45%)
Female	17/31 (55%)
Age
Median age (range)	67 (45–86)
Age ≥60	21/31 (68%)
Age ≥70	15/31 (48%)
ECOG status
ECOG, median (range)	2 (1–3)
ECOG 1	14/31 (45%)
ECOG 2	12/31 (39%)
ECOG 3	5/31 (16%)
Diagnosis
De novo AML	15/31 (48%)
Secondary AML	16/31 (52%)
Post-MDS/MPN	4/31 (13%)
Therapy-related AML	12/31 (39%)
Karyotype
Non-adverse	17/31 (55%)
Adverse	14/31 (45%)
Complex	5/31 (16%)
ELN2017 risk group
Favorable	5/31 (16%)
Intermediate	8/31 (26%)
Adverse	18/31 (58%)
AML characteristics
Bone marrow blast count, median (min-max)*	27% (1–94)
Proliferative disease**	9/31 (29%)
Extramedullar AML	8/31 (26%)
Number of previous treatment lines
Median (range)	2 (1–4)
1	11/31 (35%)
2	11/31 (35%)
3	8/31 (26%)
4	1/31 (3%)
Previous treatment
Previous intensive chemotherapy	19/31 (61%)
Primary refractory (after 1 or 2 induction cycles)	4/31 (13%)
Previous low-intensity therapy only (HMA/LDAraC ± venetoclax)	12/31 (39%)
Previous venetoclax exposure	14/31 (45%)
Previous alloSCT	9/31 (29%)
Median time from alloSCT to relapse, days (range)	89 (51–3177)
Relapse within 12 months of alloSCT	8/9 (89%)

*2 patients had extramedullar R/R AML

**Proliferative disease criteria: WBC>10 × 109/l with blasts and rapidly progressing leukocytosis and/or rapidly progressing extramedullar lesions

ELN European Leukemia Network, ECOG Eastern Cooperative Oncology Group performance status, AlloSCT allogeneic stem cell transplantation, AML acute myeloid leukemia, HMA hypomethylating agents, LDAraC low-dose Cytarabine, MDS myelodysplastic syndrome, MPN myeloproliferative neoplasm

Glasdegib + LDAraC treatment

A median of 2 (1–7) glasdegib + LDAraC cycles were administered. Twenty-nine percent (9/31) of the patients received at least 4 cycles. Additional hydroxyurea was used in 16% (5/31) of cases due to hyperproliferation. Treatment was stopped due to disease progression (55%, 17/31), toxicity (6%, 2/31), death in aplasia (6%, 2/31), and alloSCT (3%, 1/31). Nine patients (29%) continue glasdegib + LDAraC treatment (Fig. 1). Ninety-three percent (7/104) of all glasdegib + LDAraC cycles were administered in the outpatient setting.

Fig. 1

Swimmer plot of 31 R/R AML patients treated with glasdegib + LDAraC

Response evaluation and survival

Response was evaluated in 94% (29/31) of cases. Two patients had died during cycle 1 before response assessment. Detailed response evaluation is summarized in Table 2 and Fig. 1. CR and CRp were confirmed in 17% (5/29) and 3% (1/29) of the patients, respectively, and one patient achieved a PR. The composite CR + CRp rate was 21% (6/29), and the overall response rate (CR + CRi + CRp + PR) was 24% (7/29). The median response duration was 2 months (0.3–-6). Stable disease was achieved in 48% (14/29) of patients whereas the remaining 28% (8/29) were diagnosed with progressive AML during treatment. Characteristics of responding and non-responding patients are shown in Table 3. Responders were older and less exposed to intensive chemotherapy compared to non-responders. Survival data are summarized in Figs. 2 and 3. The median overall survival was 3.9 months for all the patients. The median follow-up time was 9.4 months. Different median survival lengths were observed in responders (CR/CRp/PR), patients achieving SD, and progressive cases: not reached vs 3.9 months vs 0.8 months, respectively (p < 0.001). In a univariate Cox regression analysis (Fig. 4), older age (≥70 years) and previous non-intensive treatment only were associated with longer survival. Previous alloSCT, hyperproliferation, ECOG status, more than 1 previous treatment line, adverse cytogenetics, or previous venetoclax exposure did not have a significant impact on survival.

Table 2

Response evaluation

	n/N (%)
Response evaluated	29/31 (94%)
Response not evaluated	2/31 (6%)
Best response
CR	5/29 (17%)
CRp	1/29 (3%)
PR	1/29 (3%)
SD	14/29 (48%)
PD	8/29 (28%)
CR + CRp	6/29 (21%)
CR + CRp + PR	7/29 (24%)
Response (CR, CRp, PR) in subgroups
Adverse cytogenetics	2/13 (15%)
Non-adverse cytogenetics	5/16 (31%)
Proliferative disease	1/9 (11%)
Post-alloSCT	0/9 (0%)
Previous intensive chemotherapy	1/18 (6%)
Primary refractory	1/4 (25%)
Previous low-intensity therapy only (HMA/LDAraC ± venetoclax)	6/11 (55%)
Previous venetoclax exposure	2/14 (28%)

CR complete remission, CRp complete remission with incomplete platelet recovery, PR partial remission, PD progressive disease, SD stable disease, alloSCT allogeneic stem cell transplantation, HMA hypomethylating agents, LDAraC low-dose Cytarabine

Table 3

Characteristics of responders and non-responders

	Responders (7)	Non-responders (22)	p
Age (median, range)	75 (67–86)	64 (45–84)	0.020
Number of previous treatment lines (median, range)	1 (1–3)	2 (1–4)	0.146
Adverse karyotype	2/7 (29%)	11/22 (50%)	0.410
ECOG (median, range)	2 (1–3)	2 (1–3)	0.889
Hyperproliferation	1/7 (14%)	8/22 (36%)	0.381
Previous intensive chemotherapy	1/7 (14%)	17/22 (77%)	0.005
Post-alloSCT	0 (0%)	9/22 (41%)	0.066
Previous venetoclax exposure	2/7 (29%)	12/22 (55%)	0.389

Proliferative disease criteria: WBC>10 × 109/l with blasts and rapidly progressing leukocytosis and/or rapidly progressing extramedullary lesions

ECOG Eastern Cooperative Oncology Group performance status, AlloSCT allogeneic stem cell transplantation

Fig. 2

Overal survival of 31 R/R AML patients treated with glasdegib + LDAraC. OS, overall survival; CI, confidence interval

Fig. 3

Overall survival of patients achieving different responses to glasdegib + LDAraC, p < 0.001. OS, overall survival; CI, confidence interval; CR, complete remission; CRp, complete remission with incomplete platelet recovery; PR, partial remission; PD, progressive disease; SD, stable disease

Fig. 4

Effect of different variables on overall survival. Proliferative disease criteria: WBC>10 × 109/l with blasts and rapidly progressing leukocytosis and/or rapidly progressing extramedullary lesions. Low-intensity therapy: hypomethylating agents/low-dose Cytarabine ± venetoclax. ECOG, Eastern Cooperative Oncology Group performance status; AlloSCT, allogeneic stem cell transplantation

Toxicity

Grade 3–5 non-hematological toxicity analysis and any grade adverse events of special interest (AESI) are summarized in Table 4. The following infectious complications were the most common: pneumonia (29%, 9/31), sepsis (23%, 7/31), and febrile neutropenia (16%, 5/31). COVID-19 was diagnosed in 6% of cases (2/31) with one fatal outcome. Of note, grade 3–5 bleeding events were also relatively common: 16% (3/31) of the patients suffered from gastrointestinal bleeding, 10% (3/31) had epistaxis, and 1 patient died due to central nervous system hemorrhage. Adverse events of special interest related to glasdegib were QT prolongation (13%, 4/31), diarrhea (6%, 2/31), alopecia (6%, 2/31), gastritis (6%, 2/31), anorhexia (6%, 2/31), and dysgeusia (3%, 1/31). Day 30 and day 60 all-cause mortality rates were 23% (7/31) and 29% (9/31), respectively.

Table 4

Toxicity profile

CNS, central nervous system; CTCAE, Common Terminology Criteria for Adverse Events

The grey shading refers to “Not evaluated”

Discussion

Efficacy and safety data of glasdegib + LDAraC in R/R AML setting are limited to only several reports. A case series published by Tavares et al. evaluated six elderly patients with R/R AML or HR-MDS who had previously received a median of 2 therapy lines [13]. Four patients achieved a stable disease whereas a progressive disease was diagnosed in the remaining 2 cases. No objective responses were observed; however, 4/6 of the patients survived longer than 6 months. Salmman et al. evaluated the efficacy of glasdegib monotherapy in R/R chronic myelomonocytic leukemia, myelodysplastic syndromes, or oligoblastic (20–30% blasts in the bone marrow) AML in a phase II study [14]. A total of 35 (mostly MDS, 4 with AML) patients (median age 73 years) were included. Stable disease was achieved in 56% of the patients, and 6% had hematological improvement (HI). No objective responses (CR/CRi/CRp/PR/MLFS) were observed. The median OS was 10.4 months for the whole group and 20.6 months for patients achieving SD or HI.

Our patients treated with glasdegib + LDAraC were also elderly and unfit; however, all of them had R/R AML, approximately half had secondary AML and/or adverse cytogenetics. Importantly, the majority had previously failed multiple lines of intensive chemotherapy, with some relapsing very early after alloSCT. The remaining patients were refractory to HMA or LDAraC-based therapies. Venetoclax was used in almost half of the cases as well. Unsurprisingly, the median survival of our poor prognosis group was only 3.9 months. We demonstrate a 21% composite CR + CRp rate which compares favorably to both R/R setting reports (no CR/CRi/CRp/PRs) and the pivotal phase II study in previously untreated AML/HR-MDS (17% CR rate) [9, 13, 14]. Achieving response (CR/CRp/PR) translated into a prolonged OS (all 7 responders are alive after the median follow-up time of 9.4 months, 2 are in remission (1 was bridged to alloSCT and 1 is still on Gilteritinib), and 5 relapsed). Three out of five of the relapsed patients are still receiving glasdegib + LDAraC without overt AML progression signaling the importance of continuous treatment beyond relapse. Almost half of our patients achieved AML stabilization and survived longer when compared to cases with progressive disease. Though debatable, this may suggest a benefit of glasdegib + LDAraC in patients without objective response as already noted in the frontline and R/R glasdegib studies [13-15].

Interestingly, adverse karyotype was not associated with worse OS in our group, which differs from the data of the BRIGHT AML 1003 study [9]. Of note, previous alloSCT, hyperproliferation, number of failed treatment lines, previous venetoclax exposure or, worse ECOG PS did not impact the OS in our analysis either. On the other hand, older age and previous exposure to only low-intensity therapies (HMAs/LDAraC ± venetoclax) were associated with longer survival. Furthermore, the ORR in non-intensively pretreated patients was 55% (6/11). This may indicate the possible benefit of glasdegib + LDAraC therapy in a subgroup of elderly R/R AML patients failing HMA treatment. These patients usually face poor prognosis due to the lack of effective salvage therapies if targetable FLT3 or IDH1/2 mutations are not present [16-18]. Our previously published data and the results of this study show that glasdegib + LDAraC may have a role in AML patients failing venetoclax [19].

Both infectious and hemorrghagic complications during glasdegib + LDAraC treatment were mainly attributable to the uncontrolled AML, and only a minority of adverse events were treatment-related. Interestingly, QT prolongation was rare, regardless of the fact that the majority of patients received multiple concomitant QT-prolonging agents (azoles, fluoroquinolones, amiodarone). Only 6% (2/31) of patients had grade 3 QT prolongation, and no episodes of life-threatening arrhythmias were observed. This may be partially explained by the prophylactic potassium and magnesium supplementation in the majority of cases and routine ECG evaluation. Other glasdegib-related toxicities (alopecia, dysgeusia, anorhexia, gastrointestinal symptoms, diarrhea) were also rare. Overall, glasdegib + LDAraC was tolerated well in patients achieving response or disease stabilization and was successfully administered in the outpatient setting.

Our study has limitations. This was a retrospective, non-randomized, single-center study with a limited number of patients and a limited observation time. Nevertheless, to the best of our knowledge, this is the first report showing that glasdegib + LDAraC induces remission in poor-risk R/R AML patients with the majority achieving at least disease stabilization.

In summary, our data demonstrate that glasdegib + LDAraC is a fairly safe, non-intensive outpatient regimen that may induce complete remission and result in prolonged survival in some R/R AML patients. Older patients after low-intensity therapy failure seem to benefit the most. Larger prospective studies are warranted.